Tuberculosis (TB) continues to be one of the Philippines’ most pressing public health challenges, with nearly 190,000 cases going undetected each year. In a transformative move aligned with the UN goal to treat 2.1 million TB cases by 2027, the Philippines Department of Health has embraced Indian innovation to revolutionize its TB response.
At the forefront is the Truenat® platform, a WHO-endorsed, ICMR-approved molecular diagnostic solution developed by Goa-based Molbio Diagnostics. Designed for portability, accuracy, and speed, the Truenat® system supports rapid testing not just for TB, but for a wide array of infectious diseases, including HIV, HPV, and Hepatitis B & C.
Currently, 68 Truenat® devices are operational across the Philippines. A pilot on Bantayan Island yielded a staggering 1008% increase in TB detection — a powerful testament to the platform’s impact.
Geographic barriers, under-resourced labs, and limited rural access have long hindered TB diagnosis in the Philippines. Truenat®, alongside the newly approved PRORAD Atlas Ultraportable X-ray system, now makes it possible to deliver end-to-end screening, diagnosis, and treatment — even in the most isolated communities.
During an official visit to Molbio’s facility in India, Philippines Health Secretary Dr. Teodoro J Herbosa commended the partnership, calling it a “beacon of innovation” and highlighting the broader strategic alliance between the two nations. “Truenat® allows for swift and accurate TB screenings, enhancing our capacity to manage and eventually eliminate TB within our borders,” he said.
This healthcare collaboration reflects a growing Indo-Philippine partnership that now exceeds $3 billion in trade, spanning pharmaceuticals, medical technology, and beyond.
Molbio Diagnostics will further its engagement with the Philippines by hosting a panel at the 31st Philippine Coalition Against Tuberculosis (PhilCAT) Annual Convention in Manila on August 14–15, 2025.
The company’s broader mission continues through projects like a multi-country R2D2 TB Network study exploring tongue-swab molecular testing — a game-changer for TB detection among children and people with HIV/AIDS.
“By bringing diagnostics to the doorstep of underserved communities, we aim to close the TB care gap and help countries build stronger, more resilient health systems,” said Shiva Sriram, President of Molbio Diagnostics.
Discover more from Allycaral
Subscribe to get the latest posts sent to your email.
